Rules-Based Medicine has announced the availability of DiscoveryMap v1.0 - a collection of quantitative immunoassays for use in advancing safety and efficiency in drug and diagnostic development.
DiscoveryMap v1.0 offers customers dynamic coverage of most physiologically relevant pathways, providing biological information and leads for further study.
The offering increases the odds of identifying protein biomarker patterns in almost any drug development or diagnostic discovery project.
DiscoveryMap v1.0 utilises Rules-Based Medicine's (RBM) proprietary multi-analyte profiling (Map) platform to quantify key blood-based biomarkers representing dozens of important biological pathways.
DiscoveryMap provides customers with robust, quantitative data.
All samples are processed in RBM's CLIA-certified lab using proprietary reagents and software to give the most accurate and reproducible protein measurements.
Multiplexing allows all of these assays to be processed from a 500 microlitre sample of serum or plasma, compared with single-plex platforms, such as Elisa, which would require upwards of 10-15 millilitres of sample.
DiscoveryMap samples are processed on an industrialised, automated platform that enables the discovery of biomarker patterns made up of multiple proteins, many with small, yet reproducibly detected changes.
New patterns can then be converted to a custom focused biomarker panel for high-throughput processing in clinical trials as a service from RBM or supplied to the customer as an optimised kit manufactured under Good Manufacturing Practice regulations.
